[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 17, 2002

Estrogen Replacement Therapy and Risk of Ovarian Cancer

Author Affiliations

Author Affiliation: Department of Obstetrics/Gynecology, Tufts University and New England Medical Center, Boston, Mass.

JAMA. 2002;288(3):368-369. doi:10.1001/jama.288.3.368

By the middle of the 20th century, it was well recognized that elderly women frequently developed severe osteoporosis, resulting in a life complicated by constant back pain and repeated fractures. By the 1970s and 1980s, it became clear that use of estrogenic substances at or near the time of menopause could prevent or treat osteoporosis, and these drugs became widely prescribed and taken. Even before the bone-sparing effects of estrogen were known, these agents were used extensively for the treatment of menopausal symptoms, primarily vasomotor instability and vaginal atrophy.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×